Bayer AG Sponsored ADR logo

Bayer AG Sponsored ADR (BAYRY)

Market Closed
11 Sep, 20:00
OTC PINK OTC PINK
$
13. 95
-0.12
-0.8529%
$
55.25B Market Cap
- P/E Ratio
10.54% Div Yield
286,800 Volume
0 Eps
$ 14.07
Previous Close
Investors:
Add Transaction
Day Range
13.86 14.09
Year Range
7.48 15.23
Want to track BAYRY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Bayer Stock Slumps After Firm Ordered To Pay More Than $2B in Latest Roundup Case

Bayer Stock Slumps After Firm Ordered To Pay More Than $2B in Latest Roundup Case

Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged cancer risk tied to its Roundup weed killer, sending shares of the German pharmaceutical drug giant down Monday.

Investopedia | 1 year ago
Is Bayer (BAYRY) Stock Outpacing Its Medical Peers This Year?

Is Bayer (BAYRY) Stock Outpacing Its Medical Peers This Year?

Here is how Bayer Aktiengesellschaft (BAYRY) and Enhabit (EHAB) have performed compared to their sector so far this year.

Zacks | 1 year ago
Bayer Shares Plunge After U.S. Court Defeat in Roundup Case

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case

Bayer said it was ordered to pay $2.1 billion in a case about its Roundup weedkiller after a jury in a Georgia state court reached a verdict in favor of the plaintiff.

Wsj | 1 year ago
Bayer hit with $2 billion Roundup verdict in US state of Georgia cancer case

Bayer hit with $2 billion Roundup verdict in US state of Georgia cancer case

Bayer was ordered by a jury in the U.S. state of Georgia to pay about $2.1 billion to a plaintiff who claimed the company's Roundup weed killer caused his cancer, the plaintiff's law firms said late on Friday.

Reuters | 1 year ago
Is Bayer (BAYRY) Stock Undervalued Right Now?

Is Bayer (BAYRY) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
Litigation, Debt, And Decline - Yet Bayer Seems Like A Buy

Litigation, Debt, And Decline - Yet Bayer Seems Like A Buy

Bayer's stock surged 24.5% since December 2024, yet remains a speculative investment due to significant risks like high debt and ongoing litigation. 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly; Pharmaceuticals saw slight growth, while Crop Science and Consumer Health declined. Bayer's 2025 outlook is uncertain, with potential sales growth of 1% at best; management remains optimistic about a turnaround by 2027.

Seekingalpha | 1 year ago
Bayer's sNDA for Kerendia Label Expansion Gets FDA's Priority Review

Bayer's sNDA for Kerendia Label Expansion Gets FDA's Priority Review

The FDA accepts and grants priority review to BAYRY's sNDA for Kerendia to treat patients with a common form of heart failure.

Zacks | 1 year ago
Bayer welcomes new law in U.S. state to better shield it against glyphosate litigation

Bayer welcomes new law in U.S. state to better shield it against glyphosate litigation

Bayer said on Monday that it welcomed a new law about to be passed in the U.S. state of Georgia to better protect the maker of crop protection chemicals against glyphosate litigation.

Reuters | 1 year ago
Bayer wins Brazil injunction in soy patent row with farmers

Bayer wins Brazil injunction in soy patent row with farmers

Germany's Bayer has won an injunction to suspend a court ruling that gave Brazilian soybean farmers the right to reimbursement for royalties paid for expired patents of genetically modified soy seeds, according to a farmer group and a statement sent by the company to stakeholders this week.

Reuters | 1 year ago
Exclusive: Bayer share drop draws market regulator's scrutiny, source says

Exclusive: Bayer share drop draws market regulator's scrutiny, source says

Germany's financial markets watchdog has started an initial probe to examine whether Bayer fairly disclosed plans to get shareholder approval for a potential capital increase, a regulatory source told Reuters on Tuesday.

Reuters | 1 year ago
Bayer told analysts of cash call plan a day before official statement

Bayer told analysts of cash call plan a day before official statement

Bayer told several brokerages about plans to seek shareholder permission to issue shares one day before formally announcing the news on Friday, which weighed heavily on the stock, analysts' notes seen by Reuters showed.

Reuters | 1 year ago
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

Here is how Bayer Aktiengesellschaft (BAYRY) and AbbVie (ABBV) have performed compared to their sector so far this year.

Zacks | 1 year ago
Loading...
Load More